How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

    The content on this page is not current guidance and is only for the purposes of the consultation process.

    Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis

    Closed for comments This consultation ended on at   Request commenting lead permission

    2 Information about fluocinolone acetonide intravitreal implant

    Anticipated marketing authorisation indication

    Fluocinolone acetonide intravitreal implant (Iluvien, Alimera Sciences) is indicated for 'prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye'.

    Dosage in the marketing authorisation

    Fluocinolone acetonide intravitreal implant is administered through intravitreal injection. Each implant contains 0.19 mg of fluocinolone acetonide and releases fluocinolone acetonide for up to 36 months.

    Price

    £5,500 per implant (excluding VAT, British national formulary online [accessed March 2019]).

    The company has a commercial arrangement (simple discount patient access scheme). This makes fluocinolone acetonide intravitreal implant available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.